argenx SE (ARGX)
- Previous Close
542.47 - Open
542.91 - Bid 390.04 x 200
- Ask 534.28 x 200
- Day's Range
531.09 - 545.98 - 52 Week Range
356.38 - 678.21 - Volume
308,994 - Avg. Volume
407,130 - Market Cap (intraday)
33.571B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
32.52 - EPS (TTM)
16.38 - Earnings Date Jul 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
746.22
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
argenx.comRecent News: ARGX
View More
Performance Overview: ARGX
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARGX
View MoreValuation Measures
Market Cap
33.11B
Enterprise Value
29.77B
Trailing P/E
33.08
Forward P/E
57.14
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.04
Price/Book (mrq)
6.02
Enterprise Value/Revenue
11.54
Enterprise Value/EBITDA
81.57
Financial Highlights
Profitability and Income Statement
Profit Margin
40.26%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.64B
Net Income Avi to Common (ttm)
1.06B
Diluted EPS (ttm)
16.38
Balance Sheet and Cash Flow
Total Cash (mrq)
3.38B
Total Debt/Equity (mrq)
0.71%
Levered Free Cash Flow (ttm)
--
Research Analysis: ARGX
View MoreResearch Reports: ARGX
View MoreArgenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
RatingPrice TargetArgenx Earnings: Strong Uptake of Vyvgart; Raising Our Fair Value Estimate to EUR 540 From EUR 491
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
RatingPrice TargetArgenx Earnings: Strong Uptake of Vyvgart; Raising Our Fair Value Estimate to EUR 540 From EUR 491
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
RatingPrice TargetArgenx Earnings: Maintaining Our Fair Value Estimate as Vyvgart Momentum Fuels Growth
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
RatingPrice Target